Epicardial Vs. Transvenous Implantable Cardioverter Defibrillators in Children

Overview

Journal Europace

Publisher Oxford University Press

Specialties Cardiology & Vascular Diseases
Physiology

Date 2023 Feb 3

PMID 36735263

Authors

Pierre Antoine Le Bos

Margaux Pontailler

Alice Maltret

Diala Kraiche

Regis Gaudin

Claudio Barbanti

Eloi Marijon

Olivier Raisky

Damien Bonnet

Victor Waldmann

Affiliations

Soon will be listed here.

Abstract

Aims: The implantable cardioverter defibrillator (ICD) has been increasingly used in children. Both epicardial and transvenous approaches are used, with controversy regarding the best option with no specific recommendations. We aimed to compare outcomes associated with epicardial vs. transvenous ICDs in children.

Methods And Results: Data were analysed from a retrospective study including all patients <18-year-old implanted with an ICD in a tertiary centre from 2003 to 2021. Outcomes were compared between epicardial and transvenous ICDs. A total of 122 children with an ICD (mean age 11.5 ± 3.8 years, 57.4% males) were enrolled, with 84 (64.1%) epicardial ICDs and 38 (29.0%) transvenous ICDs. Early (<30 days) ICD-related complications were reported in 17 (20.2%) patients with an epicardial ICD vs. 0 (0.0%) with a transvenous ICD (P = 0.002). Over a mean follow-up of 4.8 ± 4.0 years, 25 (29.8%) patients with an epicardial ICD and 9 (23.7%) patients with a transvenous ICD experienced at least one late ICD-related complication [hazard ratio (HR) 1.8, 95% confidence interval (CI) 0.8-4.0]. Implantable cardioverter defibrillator lead dysfunction occurred in 19 (22.6%) patients with an epicardial ICD vs. 3 (7.9%) with a transvenous ICD (HR 5.7, 95% CI 1.3-24.5) and was associated with a higher incidence of ICD-related reintervention (HR 3.0, 95% CI 1.3-7.0). After considering potential confounders, especially age and weight at implantation, this association was no longer significant (P = 0.112). The freedom from ICD lead dysfunction was greater in patients with pleural coils than in those with epicardial coils (HR 0.38, 95% CI 0.15-0.96).

Conclusion: In children, after a consideration of patient characteristics at implantation, the burden of complications and ICD lead dysfunction appears to be similar in patients with epicardial and transvenous devices. Pleural coils seem to be associated with better outcomes than epicardial coils in this population.

Clinical Trial Registration: NCT05349162.

Citing Articles

Implantable cardioverter defibrillator therapy in paediatric patients for primary vs. secondary prevention.

Thuraiaiyah J, Philbert B, Jensen A, Xing L, Joergensen T, Lim C Europace. 2024; 26(9).

PMID: 39345160 PMC: 11440178. DOI: 10.1093/europace/euae245.

Congenital Long QT Syndrome in Children and Adolescents: A General Overview.

Balestra E, Bobbo M, Cittar M, Chicco D, DAgata Mottolese B, Barbi E Children (Basel). 2024; 11(5).

PMID: 38790576 PMC: 11119491. DOI: 10.3390/children11050582.

New Guidelines of Pediatric Cardiac Implantable Electronic Devices: What Is Changing in Clinical Practice?.

Silvetti M, Colonna D, Gabbarini F, Porcedda G, Rimini A, DOnofrio A J Cardiovasc Dev Dis. 2024; 11(4).

PMID: 38667717 PMC: 11050217. DOI: 10.3390/jcdd11040099.

References

Stout K, Daniels C, Aboulhosn J, Bozkurt B, Broberg C, Colman J . 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018; 73(12):e81-e192. DOI: 10.1016/j.jacc.2018.08.1029. View

Pyngottu A, Werner H, Lehmann P, Balmer C . Health-Related Quality of Life and Psychological Adjustment of Children and Adolescents with Pacemakers and Implantable Cardioverter Defibrillators: A Systematic Review. Pediatr Cardiol. 2018; 40(1):1-16. DOI: 10.1007/s00246-018-2038-x. View

Stiles M, Fauchier L, Morillo C, Wilkoff B . 2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm. 2019; 17(1):e220-e228. DOI: 10.1016/j.hrthm.2019.02.034. View

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007; 335(7624):806-8. PMC: 2034723. DOI: 10.1136/bmj.39335.541782.AD. View

Jordan C, Freedenberg V, Wang Y, Curtis J, Gleva M, Berul C . Implant and clinical characteristics for pediatric and congenital heart patients in the national cardiovascular data registry implantable cardioverter defibrillator registry. Circ Arrhythm Electrophysiol. 2014; 7(6):1092-100. DOI: 10.1161/CIRCEP.114.001841. View

Czosek R, Meganathan K, Anderson J, Knilans T, Marino B, Heaton P . Cardiac rhythm devices in the pediatric population: utilization and complications. Heart Rhythm. 2011; 9(2):199-208. DOI: 10.1016/j.hrthm.2011.09.004. View

Tomaske M, Pretre R, Rahn M, Bauersfeld U . Epicardial and pleural lead ICD systems in children and adolescents maintain functionality over 5 years. Europace. 2008; 10(10):1152-6. DOI: 10.1093/europace/eun214. View

Reeves J, Kim J, Mitchell M, McCanta A . Implantation of the subcutaneous implantable cardioverter-defibrillator with retroperitoneal generator placement in a child with hypoplastic left heart syndrome. HeartRhythm Case Rep. 2017; 1(4):176-179. PMC: 5419250. DOI: 10.1016/j.hrcr.2015.01.016. View

Silvetti M, Pazzano V, Verticelli L, Battipaglia I, Saputo F, Albanese S . Subcutaneous implantable cardioverter-defibrillator: is it ready for use in children and young adults? A single-centre study. Europace. 2018; 20(12):1966-1973. DOI: 10.1093/europace/euy139. View

10.

Bogush N, Espinosa R, Cannon B, Wackel P, Okamura H, Friedman P . Selecting the right defibrillator in the younger patient: Transvenous, epicardial or subcutaneous?. Int J Cardiol. 2017; 250:133-138. DOI: 10.1016/j.ijcard.2017.09.213. View

11.

Baskar S, Bao H, Minges K, Spar D, Czosek R . Characteristics and Outcomes of Pediatric Patients Who Undergo Placement of Implantable Cardioverter Defibrillators: Insights From the National Cardiovascular Data Registry. Circ Arrhythm Electrophysiol. 2018; 11(9):e006542. DOI: 10.1161/CIRCEP.118.006542. View

12.

Muller M, Dieks J, Backhoff D, Schneider H, Ruschewski W, Tirilomis T . Efficacy and safety of non-transvenous cardioverter defibrillators in infants and young children. J Interv Card Electrophysiol. 2018; 54(2):151-159. DOI: 10.1007/s10840-018-0451-y. View

13.

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

14.

Radbill A, Triedman J, Berul C, Fynn-Thompson F, Atallah J, Alexander M . System survival of nontransvenous implantable cardioverter-defibrillators compared to transvenous implantable cardioverter-defibrillators in pediatric and congenital heart disease patients. Heart Rhythm. 2009; 7(2):193-8. DOI: 10.1016/j.hrthm.2009.10.014. View

15.

Winkler F, Dave H, Weber R, Gass M, Balmer C . Long-term outcome of epicardial implantable cardioverter-defibrillator systems in children: results justify its preference in paediatric patients. Europace. 2017; 20(9):1484-1490. DOI: 10.1093/europace/eux284. View

16.

Schneider A, Burkhart H, Ackerman M, Dearani J, Wackel P, Cannon B . Minimally invasive epicardial implantable cardioverter-defibrillator placement for infants and children: An effective alternative to the transvenous approach. Heart Rhythm. 2016; 13(9):1905-12. DOI: 10.1016/j.hrthm.2016.06.024. View

17.

Silka M, Kron J, Dunnigan A, Dick 2nd M . Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. The Pediatric Electrophysiology Society. Circulation. 1993; 87(3):800-7. DOI: 10.1161/01.cir.87.3.800. View

18.

Griksaitis M, Rosengarten J, Gnanapragasam J, Haw M, Morgan J . Implantable cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutaneous defibrillation. Europace. 2013; 15(4):523-30. DOI: 10.1093/europace/eus388. View

19.

Sato A, Hasegawa Y, Haniu H, Shiraishi S, Yagihara N, Iijima K . Replacement of an Implantable Cardioverter-Defibrillator (ICD) with a New Standard Subcutaneous ICD System in a Patient with Jervell and Lange-Nielsen Syndrome. Int Heart J. 2019; 60(5):1206-1210. DOI: 10.1536/ihj.19-076. View

20.

Berul C, Van Hare G, Kertesz N, Dubin A, Cecchin F, Collins K . Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. J Am Coll Cardiol. 2008; 51(17):1685-91. DOI: 10.1016/j.jacc.2008.01.033. View